ArticleAnnals of medicine2025

Disitamab vedotin plus programmed death-1 inhibitor for pre-treated HER2 overexpressed advanced gastric cancer: a multicentre retrospective real-world study.

Xiao Yan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.